title: [A case report of complete response by TS-1 and paclitaxel combination chemotherapy for advanced gastric cancer].
abstract: We report a case in which combination chemotherapy of TS-1 and paclitaxel was effective for gastric cancer with malignant ascites, metastatic ovarian cancer and hydronephrosis. Judging from the above issue, the stage was IV and the type was Borrmann 4. The chemotherapy schedule was adjusted at the patient' s request without hindering her activities of daily living. The patient was a 53-year-old woman who suffered from gastric cancer as having malignant ascites and metastatic ovarian tumor. As an outpatient, she was treated with combination chemotherapy of TS-1 and paclitaxel for 2 cycles. The ascites had remarkably disappeared after 2 cycles. The adverse event was alopecia (grade 2), but she could continue the chemotherapy as an outpatient treatment. After completing 5 cycles of chemotherapy, we recognized the primary tumor as an endoscopic complete response.
authors.affiliation: Dept. of Internal Medicine, Osaka Seamen' s Insurance Hospital.
authors.forename: Takayuki
authors.initials: T
authors.lastname: Kodama
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Ishida
authors.forename: Takeshi
authors.initials: T
authors.lastname: Okino
authors.forename: Rieko
authors.initials: R
authors.lastname: Okamoto
authors.forename: Hitomi
authors.initials: H
authors.lastname: Takahashi
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Hayashi
authors.forename: Kisao
authors.initials: K
authors.lastname: Mori
authors.forename: Masahiko
authors.initials: M
authors.lastname: Noguchi
mesh_terms: D000505:Alopecia / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D018279:Carcinoma, Signet Ring Cell / Q000188:drug therapy* / Q000556:secondary; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000556:secondary; D010094:Oxonic Acid / Q000008:administration & dosage / Q000009:adverse effects; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D011788:Quality of Life; D012074:Remission Induction; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D017239:Paclitaxel